Table 5.
Positive cytotoxic T lymphocyte and delayed‐type hypersensitivity responses against RNF43‐derived and TOMM34‐derived peptides
| Cycle 1 | Cycle 2 | |||||||
|---|---|---|---|---|---|---|---|---|
| Cohort 1 0.3 mg/body | Cohort 2 1.0 mg/body | Cohort 3 3.0 mg/body | Cohort 4 6.0 mg/body | Cohort 1 0.3 mg/body | Cohort 2 1.0 mg/body | Cohort 3 3.0 mg/body | Cohort 4 6.0 mg/body | |
| No. patients (patient with positive response/total patients assessed) | ||||||||
| CTL response (ELISpot assay) | ||||||||
| RNF43 | 2/6 | 3/5 | 3/6 | 2/4 | 0/2 | 0/1 | 3/5 | 1/2 |
| TOMM34 | 0/6 | 3/5 | 3/6 | 3/4 | 0/2 | 0/1 | 1/5 | 0/2 |
| (ICS assay) | ||||||||
| RNF43 | 4/6 | 3/5 | 4/6 | 0/5 | 0/2 | 1/1 | 3/5 | 0/3 |
| TOMM34 | 1/6 | 5/5 | 3/6 | 1/5 | 0/2 | 1/1 | 3/5 | 1/3 |
| DTH reaction | ||||||||
| Redness | 3/6 | 2/6 | 5/6 | 3/5 | 1/3 | 1/2 | 5/5 | 1/3 |
| Induration | 1/6 | 1/6 | 1/6 | 0/5 | 0/3 | 0/2 | 0/5 | 0/3 |
CTL, cytotoxic T lymphocyte; DTH, delayed‐type hypersensitivity; ELISpot, Enzyme‐Linked ImmunoSpot; ICS, intracellular cytokine staining; RNF43, ring finger protein 43; TOMM34, translocase of outer mitochondrial membrane 34.